Perioperative Morbidity and Mortality of Laparoscopic Sleeve Gastrectomy (LSG) in a Single-Surgeon Experience on 892 Patients Over 11 Years

World J Surg. 2023 Nov;47(11):2809-2815. doi: 10.1007/s00268-023-07123-0. Epub 2023 Aug 7.

Abstract

Background: Laparoscopic sleeve gastrectomy (LSG) has been the most frequently performed bariatric procedure since 2014, with continually growing popularity. This study aimed to present our 30-day morbidity and mortality following LSG over a period of 11 years.

Patients and methods: This is a retrospective study that was based on prospectively collected data from patients undergoing LSG by the same surgeon from July 2011 to the end of August 2022. The LSG-associated 30-day morbidity and mortality and the risk factors for 30-day morbidity were assessed.

Results: This study included 892 patients who underwent LSG over the course of 11 years. Early postoperative adverse events were encountered in 16 patients (1.79%). Overall, twelve patients (1.35%) required blood transfusions, and two patients (0.22%) required ICU admission. The re-operation rate was 0.9% (n = 8) and the mortality rate was 0.22% (n = 2). The patient's BMI, hypertension, and revisional surgery were marginally significant/significant predictors of early postoperative morbidity. The mean EBWL% was 63.8 ± 15.55 at the 6-month follow-up.

Conclusion: This study confirms the previously reported LSG's short-term safety in terms of a low rate of 30-day postoperative morbidity and mortality. Preoperative BMI, hypertension, and revisional surgery are risk factors for 30-day morbidity and mortality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gastrectomy / adverse effects
  • Gastrectomy / methods
  • Gastroplasty* / adverse effects
  • Humans
  • Hypertension* / etiology
  • Laparoscopy* / methods
  • Morbidity
  • Obesity, Morbid* / surgery
  • Retrospective Studies
  • Surgeons*
  • Treatment Outcome